Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235099 · ClinicalTrials.gov registry record · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
A Phase 3 study, sponsored by Curium US.
- Completed
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
NCT06235099 is a Phase 3 study that has completed, run by Curium US. The registered enrollment target is 235 participants.
The verdict
NCT06235099, a Phase 3 study, has completed, sponsored by Curium US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
Study Summary
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Interventions
- DRUG Copper Cu 64 PSMA I&T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06235099
The ClinicalTrials.gov registry entry for NCT06235099 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curium US, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Copper Cu 64 PSMA I&T is the first listed.
NCT06235099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06235099 about?
NCT06235099 is a clinical study titled "Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer". This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
What is the current status of trial NCT06235099?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2024-04-01. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT06235099?
The interventions under investigation include: Copper Cu 64 PSMA I&T (DRUG).
Who is sponsoring clinical trial NCT06235099?
This trial is sponsored by Curium US, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.